1384878-07-2

Upstream product

• 1384878-29-8 3-(tert-butoxy)-1-[6-(2{4}-triaz-2-yn-1-ylmethyl)pyridazin-3-yl]-4-{[4-(propan-2-yl)phenyl]carbonyl}-5-[4-(trifluoromethoxy)phenyl]-2,5-dihydro-1H-pyrrol-2-one 
• 1384878-26-5 3-(tert-butoxy)-1-[6-(chloromethyl)pyridazin-3-yl]-4-{[4-(propan-2-yl)phenyl]carbonyl}-5-[4-(trifluoromethoxy)phenyl]-2,5-dihydro-1H-pyrrol-2-one 
• 1384878-25-4 3-(tert-butoxy)-1-(6-methylpyridazin-3-yl)-4-{[4-(propan-2-yl)phenyl]carbonyl}-5-[4-(trifluoromethoxy)phenyl]-2,5-dihydro-1H-pyrrol-2-one 
• 1260597-59-8 3-hydroxy-4-(4-isopropyl-benzoyl)-1-(6-methyl-pyridazin-3-yl)-5-(4-trifluoromethoxy-phenyl)-1,5-dihydro-pyrrol-2-one 
• 645-13-6 4-isopropylacetophenone 
• 852814-99-4 ethyl 4-[4-(1-methylethyl)phenyl]-2,4-dioxobutanoate 

Relevant academic research and scientific papers

1-(6-MEMBERED AZO-HETEROCYCLIC)-2,5-DIHYDRO-1H-PYRROL-2-ONE DERIVATIVES AS ANTI-HEPATITIS C VIRUS, THE PHARMACEUTICAL COMPOSITION THEREOF AND THEIR THERAPEUTIC USE

The present invention concerns 1-(6-memberedazo-heterocyclic)-2,5-dihydro–1H–pyrrol–2-one compoundsof the following formula (I) or a salt, solvate, tautomer, isotope, enantiomer, diastereoisomer or racemic mixture thereof: the pharmaceutical composition thereof and their therapeutic use as inhibitors of Hepatitis C virus.